Form 4: TransMedics Director James Tobin Receives RSU Grant

Director James R. Tobin acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Summary

• Director James R. Tobin was granted 2,922 restricted stock units (RSUs) on May 20, 2026.
• Each RSU represents a contingent right to receive one share of TransMedics Group, Inc. common stock.
• Following this transaction, Mr. Tobin holds 6,981 shares directly.
• Mr. Tobin maintains indirect ownership of 155,146 shares via the James R. Tobin 2012 Trust and 18,000 shares via The Tobin 2024 Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• The grant of equity aligns the director's interests with those of long-term shareholders.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is a standard practice among mid-cap medical technology companies to ensure board retention and alignment.
• The volume of shares granted is consistent with typical director compensation packages for companies of similar market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the granted RSUs according to the company's equity incentive plan.

Key Dates

Keywords

TransMedics, TMDX, Insider Trading, Form 4, Equity Compensation, Director Ownership